Literature DB >> 1705987

Identification of the region including the epitope for a monoclonal antibody which can neutralize human parvovirus B19.

H Sato1, J Hirata, M Furukawa, N Kuroda, H Shiraki, Y Maeda, K Okochi.   

Abstract

In this study, we identified a region in the human parvovirus structural protein which involves the neutralization of the virus by a monoclonal antibody and site-specific synthetic peptides. A newly established monoclonal antibody reacted with both viral capsid proteins VP1 and VP2. The epitope was found in six strains of independently isolated human parvovirus B19. The monoclonal antibody could protect colony-forming unit erythroid in human bone marrow cell culture from injury by the virus. The monoclonal antibody reacted with only 1 of 12 peptides that were synthesized according to a predicted amino acid sequence based on nucleotide sequences of the coding region for the structural protein of B19 virus. The sequence recognized by the antibody was a site corresponding to amino acids 328 to 344 from the amino-terminal portion of VP2. This evidence suggests that the epitope of the viral capsid protein is located on the surface of the virus and may be recognized by virus-neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1705987      PMCID: PMC239969     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia.

Authors:  G J Kurtzman; B Cohen; P Meyers; A Amunullah; N S Young
Journal:  Lancet       Date:  1988-11-19       Impact factor: 79.321

2.  Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis.

Authors:  R O Shade; M C Blundell; S F Cotmore; P Tattersall; C R Astell
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

3.  Intrauterine parvovirus infection associated with hydrops fetalis.

Authors:  T Brown; A Anand; L D Ritchie; J P Clewley; T M Reid
Journal:  Lancet       Date:  1984-11-03       Impact factor: 79.321

4.  Aplastic crisis due to parvovirus infection in pyruvate kinase deficiency.

Authors:  J R Duncan; C B Potter; M D Cappellini; J B Kurtz; M J Anderson; D J Weatherall
Journal:  Lancet       Date:  1983-07-02       Impact factor: 79.321

5.  Serologically proved intrauterine infection with parvovirus.

Authors:  P D Knott; G A Welply; M J Anderson
Journal:  Br Med J (Clin Res Ed)       Date:  1984-12-15

Review 6.  Protein blotting: principles and applications.

Authors:  J M Gershoni; G E Palade
Journal:  Anal Biochem       Date:  1983-05       Impact factor: 3.365

7.  Detection of antibodies to human T-lymphotropic virus type I by using synthetic peptides.

Authors:  N Kuroda; Y Washitani; H Shiraki; H Kiyokawa; M Ohno; H Sato; Y Maeda
Journal:  Int J Cancer       Date:  1990-05-15       Impact factor: 7.396

8.  Novel transcription map for the B19 (human) pathogenic parvovirus.

Authors:  K Ozawa; J Ayub; Y S Hao; G Kurtzman; T Shimada; N Young
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

9.  Direct demonstration of the human parvovirus in erythroid progenitor cells infected in vitro.

Authors:  N Young; M Harrison; J Moore; P Mortimer; R K Humphries
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

10.  Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver.

Authors:  N Yaegashi; H Shiraishi; T Takeshita; M Nakamura; A Yajima; K Sugamura
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

View more
  17 in total

1.  Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface.

Authors:  S J Rosenfeld; K Yoshimoto; S Kajigaya; S Anderson; N S Young; A Field; P Warrener; G Bansal; M S Collett
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

2.  Identification and mapping of neutralizing epitopes of human parvovirus B19 by using human antibodies.

Authors:  H Sato; J Hirata; N Kuroda; H Shiraki; Y Maeda; K Okochi
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

3.  A second neutralizing epitope of B19 parvovirus implicates the spike region in the immune response.

Authors:  K Yoshimoto; S Rosenfeld; N Frickhofen; D Kennedy; R Hills; S Kajigaya; N S Young
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

4.  Mapping Antigenic Epitopes on the Human Bocavirus Capsid.

Authors:  Shweta Kailasan; Jamie Garrison; Maria Ilyas; Paul Chipman; Robert McKenna; Kalle Kantola; Maria Söderlund-Venermo; Indrė Kučinskaitė-Kodzė; Aurelija Žvirblienė; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

5.  Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions.

Authors:  T Saikawa; S Anderson; M Momoeda; S Kajigaya; N S Young
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

6.  Subunit interaction in B19 parvovirus empty capsids.

Authors:  S J Rosenfeld; N S Young; D Alling; J Ayub; C Saxinger
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

7.  Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins.

Authors:  A Gigler; S Dorsch; A Hemauer; C Williams; S Kim; N S Young; S Zolla-Pazner; H Wolf; M K Gorny; S Modrow
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Identification and mapping of functional domains on human T-cell lymphotropic virus type 1 envelope proteins by using synthetic peptides.

Authors:  Y Sagara; Y Inoue; H Shiraki; A Jinno; H Hoshino; Y Maeda
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

Review 9.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

10.  High mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient host.

Authors:  Alberto López-Bueno; Mauricio G Mateu; José M Almendral
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.